Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377214 | 1.00 | NCF1 (0.37) | NCF1CXCR4RORCPOLBSMN1; SMN2 | |
| SCHEMBL3379518 | 0.87 | CXCR4 (0.41) | NCF1CXCR4POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL3377529 | 0.85 | RORC (0.33) | CXCR4RORCPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL3377222 | 0.83 | POLB (0.35) | CXCR4RORCPOLBSMN1; SMN2KDM4E | |
| SCHEMBL3378843 | 0.82 | KDM4E (0.46) | NCF1CXCR4POLBKDM4EALDH1A1 | |
| SCHEMBL3381143 | 0.82 | KDM4E (0.46) | NCF1CXCR4POLBKDM4EALDH1A1 | |
| SCHEMBL3380494 | 0.82 | RORC (0.38) | RORCPOLBSMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL3380491 | 0.82 | RORC (0.38) | RORCPOLBSMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL3442332 | 0.80 | HRH3 (0.45) | RORCSMN1; SMN2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL3442329 | 0.80 | HRH3 (0.45) | RORCSMN1; SMN2L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | NCF1 3992/4885CXCR4 397/4885RORC 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.